United States CAR-T Cell Therapy Market Is Expected to Dominate by Blood Cancer Type of Hereditary Cancer Through 2028
Rising prevalence of cancer
is expected to drive the growth of the market in the forecast period, 2018-2028.
According to TechSci Research report, “United States CAR-T Cell Therapy Market- By Region, Forecast and
Opportunities, 2018-2028”, the United States CAR-T Cell Therapy Market is expected to grow with an
impressive CAGR during the forecast period 2018-2028. The rise in prevalence of
cancer, growing awareness amongst the key market players, recent developments, shows
the growth of CAR-T Cell Therapy Market.
The Chimeric Antigen
Receptor (CAR) T cell therapy is an advanced form of cancer treatment, in which
healthcare researchers causes change to T-cells in the lab and then infuse into
the body of cancer patient, so they can destroy cancer cells. CAR T-cell
therapy is used to enhance the immune response especially T-cells against
cancerous cells.
Furthermore, the increase
in therapy’s adoption and utilization. CAR-T therapy has emerged as a promising
new treatment option for cancer patients, offering personalized therapy with
potentially curative outcomes. Below are some of the driving factors of the
United States CAR-T Cell Therapy Market.
One of the primary restraining factors is
the limited availability of CAR-T therapy. CAR-T therapy is a relatively new
treatment option, and there are only a few approved CAR-T products available in
the United States. Additionally, the manufacturing process for CAR-T therapy is
complex and time-consuming, which limits the number of patients who can receive
the treatment. The limited availability of CAR-T therapy makes it difficult for
patients to access the treatment, particularly those who live in rural or
remote areas where access to healthcare is limited.
Browse over 30 market data Figures
spread through 70 Pages and an in-depth TOC on "United States CAR-T Cell Therapy Market"
The United States CAR-T Cell
Therapy Market can be segmented by product type, tumor type, indication,
treatment type, targeted antigen, end user, and region. Based on product type,
the market can be segmented into Yescarta (Axicabtagene Ciloleucel), Kymriah
(Tisagenlecleucel), Tecartus (Brexucabtagene Autoleucel), Breyanzi
(Lisocabtagene Maraleucel), Abecma (Idecabtagene Vicleucel), and others. The Yescarta
(Axicabtagene Ciloleucel) segment is expected to show an impressive growth in
forecast period due to the increase in adoption of Yescarta (Axicabtagene Ciloleucel)
medicine for treatment of relapsed or refractory large B-cell lymphoma,
relapsed or refractory follicular lymphoma.
Based on indication, the
market can be segmented into Diffused Large B-Cell Lymphoma (DLBCL), Acute
Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle Cell Lymphoma
(MCL), and others. The Acute Lymphoblastic Leukemia (ALL) segment is expected
to show an impressive growth in forecast period due to increase in awareness of
CAR T-cell therapeutics for treatment of acute lymphoblastic leukemia and
expected launch of these drug for treatment of acute lymphoblastic leukemia
regarding testing of blood T-cell cancer.
Based on the end user, the
market can be classified into the market can be segmented into Hospitals,
Specialty Clinics, Ambulatory Surgical Centers, and Others. The Hospitals segment
is expected to show an impressive growth in forecast period due to well-equipped
and established operation theatre and rise in patient admission.
Major companies operating
in United States CAR-T Cell Therapy Market include:
- Gilead
Sciences, Inc (US)
- Novartis
United States
- AbbVie Inc.
- Myriad
Genetics
- NeoGenomics
Laboratories
- Intellia
Therapeutics (US)
- Agilent Technologies,
Inc. (US)
- Abcam plc.
- Bio-Techne.
(ExoDx)
- Sangamo
Therapeutics, Inc. (US)
Download Free Sample Report
Customers
can also request for 10% free customization on this report.
“United States CAR-T Cell Therapy
Market is expected to witness significant growth during the forecast period on
account of rising awareness for different therapies. An increase in number of cancer
cases further supports the demand for CAR-T Cell Therapy Market in United
States. Additionally, increase in emergence of players developing new therapies
and treatment is expected to create lucrative opportunities for the market
growth in the next few years” said Mr. Karan Chechi, Research Director
with TechSci Research, a research-based global management consulting firm.
“United
States CAR-T Cell Therapy Market, By Product Type (Yescarta (Axicabtagene
Ciloleucel), Kymriah (Tisagenlecleucel), Tecartus (Brexucabtagene Autoleucel),
Breyanzi (Lisocabtagene Maraleucel), Abecma (Idecabtagene Vicleucel), Others),
By Tumor Type (Hematological Malignancies, Solid Tumors), By Indication
(Diffused Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular
Lymphoma (FL), Mantle Cell Lymphoma (MCL), Others), By Treatment Type (Single
Treatment, Combination Treatment), By Targeted Antigen (CD 19, BCMA (B-Cell
Maturation Antigen), Others), By End User (Hospitals, Specialty Clinics,
Ambulatory Surgical Centers, Others), By Region, Competition Forecast &
Opportunities, 2028”,
has evaluated the future growth potential of United States CAR-T Cell Therapy
Market and provides statistics & information on market size, structure, and
future market growth. The report intends to provide innovative market
intelligence and help decision makers take sound investment decisions. Besides,
the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in United States CAR-T Cell
Therapy Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com